<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>Inhibition mTORC1 pathway suppresses <br /> intestinal polyp formation reduces <br /> mortality Apc&#226;&#338;&#172;716 mice <br /> Teruaki Fujishita*, Koji Aoki*, Heidi A. Lane&#226;&#8364;&#160;, Masahiro Aoki*, Makoto M. Taketo*&#226;&#8364;&#161; <br /> *Department Pharmacology, Graduate School Medicine, Kyoto University, Yoshida-Konoe&#194;&#180;-cho, Sakyo-ku, Kyoto 606-8501, Japan; &#226;&#8364;&#160;Department of <br /> Oncology, Novartis Institutes BioMedical Research, Novartis Pharma AG, CH-4002 Basel, Switzerland <br />  <br /> Edited George F. Vande Woude, Van Andel Research Institute, Grand Rapids, MI, approved July 25, 2008 (received review January 5, 2008) <br />  <br /> The mammalian target rapamycin (mTOR) serine/threonine                caused activation PI3K/Akt pathway (5, 6). Based on <br /> kinase regulates cell growth mTOR complex 1 (mTORC1),                results, clinical trials drugs aimed at <br /> whose activation implicated human cancers.                   treatment various malignancies including lymphoma, sar- <br /> However, mTORC1&#226;&#8364;&#8482;s status gastrointestinal tumors              coma, glioblastoma (7) progress. <br /> characterized thoroughly. We mTORC1 path-                    Colorectal cancer leading causes cancer deaths. <br /> way activated increased expression mTOR protein             Most human colorectal cancers suffer somatic mutations the <br /> intestinal polyps Apc&#226;&#338;&#172;716 heterozygous mutant mouse,                 adenomatous polyposis coli (APC) tumor suppressor gene, which <br /> model human familial adenomatous polyposis. An 8-week                     leads activation Wnt signaling &#226;?&#164;-catenin stabiliza- <br /> treatment RAD001 (everolimus) suppressed mTORC1                      tion. Accumulated &#226;?&#164;-catenin translocates nucleus <br /> activity polyps inhibited proliferation adenoma           binds activates TCF/LEF transcription factors (8). <br /> cells tumor angiogenesis, significantly reduced          <span id='am-240' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-241' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-242' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-243' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-244' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-245' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-246' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-247' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-248' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-249' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-250' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-251' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-252' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-253' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-254' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-255' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-256' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-257' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-258' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-259' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-260' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-261' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-262' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-263' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-264' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-265' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-266' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-267' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-268' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-269' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-270' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-271' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-272' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-273' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-274' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-275' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-276' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-277' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-278' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-279' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-280' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-281' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-282' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-283' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-284' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-285' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-286' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-287' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-288' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-289' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-290' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-291' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-292' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-293' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-294' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-295' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-296' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-297' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-298' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-299' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-300' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-301' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-302' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-303' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-304' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-305' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-306' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-307' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-308' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-309' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-310' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-311' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-312' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-313' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-314' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-315' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-316' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-317' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span>Mutation</span> APC gene appears triggering event in <br /> only number polyps size. &#226;?&#164;-Catenin knock-               colorectal tumorigenesis, germ-line mutations cause <br /> down colon cancer cell lines reduced mTOR level                intestinal polyposis humans mice (9). <br /> thereby inhibited mTORC1 signaling. These results suggest               In present study, demonstrated mTORC1 <br /> the Wnt signaling contributes mTORC1 activation                pathway activated intestinal polyps Apc&#226;&#338;&#172;716 mice, mouse <br /> increased level mTOR activation plays important               model familial adenomatous polyposis (FAP). A novel mTOR <br /> roles intestinal polyp formation growth. Indeed, long-             inhibitor RAD001 (everolimus) showed marked antitumor effects <br /> term RAD001 treatment significantly reduced mortality                  mice, targeting polyp epithelial cells vascular <br /> Apc&#226;&#338;&#172;716 mice. Thus, propose mTOR inhibitors                endothelial cells. We mTOR protein level is <br /> efficacious therapy prevention colonic adenomas                regulated &#226;?&#164;-catenin, account mTORC1 <br /> cancers Wnt signaling activation.                                        activation colon polyps cancers &#226;?&#164;-catenin stabilization. <br /> adenoma &#229;&#8230;&#169; colon cancer &#229;&#8230;&#169; mammalian target rapamycin &#229;&#8230;&#169;                      Results <br /> RAD001 &#229;&#8230;&#169; rapamycin <br />                                                                               The mTOR Signaling Pathway Is Activated Apc&#226;&#338;&#172;716 Intestinal <br />                                                                               Polyps. <span id='am-5' about='protege:TO' typeof='owl:Thing'>To</span> investigate activation status mTOR signal- <br />  <br /> T    mammalian target rapamycin (mTOR) serine/ <br />      threonine kinase belongs phosphoinositide 3- <br /> kinase related kinase family. mTOR plays essential roles in <br />                                                                               ing pathway intestinal polyps induced Wnt signaling <br />                                                                               activation, examined phosphorylation S6, cata- <br />                                                                               lyzed S6 kinase mTOR-dependent manner (10), the <br /> regulation cell growth, proliferation, motility com-              intestinal polyps normal ileum Apc&#226;&#338;&#172;716 mice. Western <br /> ponent distinct signaling complexes, mTOR complex 1                    blot analysis showed S6 phosphorylation elevated in <br /> (mTORC1) mTOR complex 2 (mTORC2). mTORC1                               ileal polyps compared normal ileum (Fig. 1A). <br /> composed mTOR, raptor, mLST8, Rheb-induced                         Immunostaining revealed phospho-S6 (p-S6) expressed <br /> activation mTORC1 enhances translation subset                      predominantly adenoma epithelial cells polyps (Fig. <br /> mRNA phosphorylation S6 kinase 4E-BP1,                         1B). In normal ileum, S6 phosphorylation mainly <br /> which induces cell growth (1). mTORC1 regulated various                 crypt epithelial cells, occasional signals villus <br /> upstream signals including emanated growth factors,                  epithelial cells (Fig. 1C). To test increased S6 <br /> nutrients, energy, stress. mTORC1 activated various                 phosphorylation intestinal polyps depends mTOR <br /> types neoplastic diseases, especially constitutive           signaling pathway, treated Apc&#226;&#338;&#172;716 mice RAD001 (10 <br /> activation PI3K&#226;&#8364;&#8220;Akt pathway. On hand,                        mg/kg) 3 days. Phosphorylation S6 normal ileum and <br /> mTORC2 composed mTOR, rictor, mLST8 plays                       adjacent polyps Apc&#226;&#338;&#172;716 mice strongly inhibited ad- <br /> important roles Akt phosphorylation Ser-473 (2)              ministration RAD001 (Fig. 1 D&#226;&#8364;&#8220;F). These results indicate that <br /> regulation actin cytoskeleton (3).                                         mTORC1 pathway strongly activated intestinal <br />    Rapamycin, natural product derived bacterial species              polyps compared normal mucosa Apc&#226;&#338;&#172;716 mouse. <br /> (Streptomyces hygroscopicus), currently used prevention of <br /> allograft rejection organ transplants. It shown that <br /> rapamycin binds FKBP12, FKBP/rapamycin                       Author contributions: T.F. M.M.T. designed research; T.F. performed research; H.A.L. <br /> complex binds inhibits mTORC1, mTORC2. In                    contributed new reagents/analytic tools; T.F., K.A., M.A., M.M.T. analyzed data; and <br /> vitro studies shown mTORC1 inhibitors induce cell-                  T.F., M.A., M.M.T. wrote paper. <br />  <br /> cycle arrest various cell types, including cancer cell lines          The authors declare conflict interest. <br /> and endothelial cells. Rapamycin-induced apoptosis                   This article PNAS Direct Submission. <br /> been demonstrated cancer cell lines (4). In addition,             &#226;&#8364;&#161;To correspondence addressed. E-mail: taketo@mfour.med.kyoto-u.ac.jp. <br />  <br /> anticancer activity mTORC1 inhibitors established                 This article contains supporting information online www.pnas.org/cgi/content/full/ <br /> in vivo studies using xenograft models mice gene-                   0800041105/DCSupplemental. <br /> targeted transgenic mice spontaneously develop tumors                 &#194;&#169; 2008 The National Academy Sciences USA <br />  <br />  <br />  <br /> 13544 &#226;&#8364;&#8220;13549 &#229;&#8230;&#169; PNAS &#229;&#8230;&#169; September 9, 2008 &#229;&#8230;&#169; vol. 105 &#229;&#8230;&#169; no. 36                                                      www.pnas.org&#229;&#8230;&#190;cgi&#229;&#8230;&#190;doi&#229;&#8230;&#190;10.1073&#229;&#8230;&#190;pnas.0800041105 <br />                                                                                      Inhibitory Effect RAD001 Polyp Formation Is Attributable to <br />                                                                                     Inhibition Tumor Cell Proliferation. Effects mTORC1 inhibi- <br />                                                                                     tors cell growth known differ cancer cell lines <br />                                                                                     (4). To gain insights mechanism polyp inhibition <br />                                                                                     RAD001, evaluated vivo cell proliferation apoptosis <br />                                                                                     RAD001-treated polyps BrdU incorporation TUNEL <br />                                                                                     assay, respectively. Treatment RAD001 reduced BrdU <br />                                                                                     labeling index adenoma cells 60% (Fig. 3 A B). In <br />                                                                                     contrast, TUNEL assay did significant difference <br />                                                                                     apoptotic frequency polyps RAD001- <br />                                                                                     treated placebo-treated mice (Fig. 3 C D). <br />                                                                                        Treatment rapamycin reduce expression cyclin D, <br />                                                                                     cyclin E, cyclin A NIH 3T3 human B cells (12, 13). <br />                                                                                     Consistently, Aoki et al. (14) reported activation the <br />                                                                                     mTOR pathway accelerated cell-cycle progression G1 S <br />                                                                                     DLD-1 cells. Because results suggested RAD001 <br />                                                                                     affected cell-cycle progression adenoma cells, exam- <br />                                                                                     ined expression cyclins polyps RAD001-treated <br />                                                                                     Apc&#226;&#338;&#172;716 mice. Although level cyclin D protein polyps <br />                                                                                     affected treatment RAD001 (data shown), <br />                                                                                     cyclin A cyclin E elevated 3.2 4.0 times, <br />                                                                                     respectively, polyps placebo-treated mice, whereas <br /> Fig. 1. Activation mTOR signaling pathway Apc&#226;&#338;&#172;716 mouse polyps.           expression cyclin E polyps reduced 33% the <br /> (A) Western blot analysis S6 phosphorylated Ser-235/236 (p-S6) total      placebo control, 3 days treatment (Fig. 3E). <br /> S6 normal ileal mucosa polyps Apc&#226;&#338;&#172;716 mouse. COX-2 known       Cyclin A expression reduced 45% polyps Apc&#226;&#338;&#172;716 <br /> to expressed polyps, little normal tissue, served     mice treated RAD001 8 weeks (Fig. 3E). These results <br /> control good preparation polyp sample. COX-1 constitutively          inhibition polyp formation RAD001 associated <br /> expressed normal tissues polyps. (B C) Immunostaining p-S6 <br />                                                                                     inhibition adenoma cell proliferation vivo without <br /> in intestinal polyp (B) normal ileum (C) Apc&#226;&#338;&#172;716 mouse. (B Inset) <br /> Subfield 4-fold higher magnification. (D) Western blot analysis p-S6 the <br />                                                                                     affecting apoptosis. <br /> normal ileal mucosa polyps Apc&#226;&#338;&#172;716 mouse treated placebo or <br /> RAD001. Mice orally treated placebo (Pla) RAD001 10 mg/kg           Treatment RAD001 Inhibits Tumor Angiogenesis. Treatment <br /> [RAD(3d)] 3 days. (E F) Immunostaining p-S6 placebo- RAD001-       RAD001 caused regression already-formed polyps <br /> treated intestinal polyp Apc&#226;&#338;&#172;716 mouse, respectively. (Scale bars: B, 250 &#226;?&#174;m;    (Fig. S1). Furthermore, large polyps Apc&#226;&#338;&#172;716 mice <br /> C, E, F, 200 &#226;?&#174;m.)                                                               treated RAD001 showed collapsed morphology top <br />                                                                                     (Fig. 2 D E). These results suggest RAD001 possess <br />                                                                                     effects inhibition adenoma cell proliferation, by <br /> Treatment RAD001 Inhibits Polyp Formation Reduces Mor-                     causes regression preexisting polyps Apc&#226;&#338;&#172;716 <br /> tality Apc&#226;&#338;&#172;716 Mouse. The activation mTORC1                           mice. Guba et al. (15) reported rapamycin treatment caused <br /> pathway Apc&#226;&#338;&#172;716 intestinal polyps suggested mTORC1                      regression transplanted CT-26, mouse colon cancer cell line, <br /> inhibitors suppress intestinal polyp formation. To inves-                     inhibition tumor cell-induced angiogenesis. Thus, we <br /> tigate role mTORC1 pathway activation polyp                           examined angiogenesis RAD001-treated Apc&#226;&#338;&#172;716 mice. Treat- <br /> formation, treated Apc&#226;&#338;&#172;716 mice RAD001 8 weeks                          ment 4 weeks significantly reduced number microves- <br /> <span id='am-3' about='protege:FROM' typeof='owl:Thing'>from</span> 6 14 weeks age (Fig. 2A). Treatment RAD001                          sels polyps (placebo, 23 &#226;&#171;&#190; 3.0 vs. RAD001, 17 &#226;&#171;&#190; 3.1) <br /> significantly inhibited polyp formation [number (Fig. 2B1)]                    affecting numbers normal intestine (placebo, <br /> and polyp expansion [size (Fig. 2 B2 B3)] Apc&#226;&#338;&#172;716 mice                    16 &#226;&#171;&#190; 1.4 vs. RAD001, 15 &#226;&#171;&#190; 1.2) (Fig. 4 A B). Several studies <br /> a dose-dependent manner (Fig. 2 B C). Large-size polyps,                        showed mTOR inhibitors reduce tumor cell <br /> particularly &#226;&#172;&#381;1.5 mm diameter,                       growth angiogenesis suppression vascular <br /> RAD001-treated Apc&#226;&#338;&#172;716 mice (Fig. 2 B C). Interestingly,                        endothelial growth factor (VEGF) expression. Because treat- <br /> RAD001-treated mouse polyps showed collapsed morphology                           ment anti-VEGF-A mAb inhibited adenoma cell growth in <br /> at (Fig. 2 D E), reminiscent COX-2                           Apcmin/&#226;&#171;&#185; mice (16), treatment RAD001 inhibit polyp <br /> inhibitor-treated polyps (11). These results suggest                           formation Apc&#226;&#338;&#172;716 mice suppression VEGF <br /> mTORC1 pathway activation essential tumor expansion                       expression. However, significant difference the <br /> the Apc&#226;&#338;&#172;716 intestinal polyps. To investigate RAD001                        VEGF expression levels polyps placebo- and <br />                                                                                     RAD001-treated Apc&#226;&#338;&#172;716 mice (Fig. 4C). In addition, prelimi- <br /> treatment cause regression already-formed polyps, we <br />                                                                                     nary determination expression levels various angio- <br /> also treated older Apc&#226;&#338;&#172;716 mice 13 21 weeks age that <br />                                                                                     genesis-related factors, including bFGF insulin-like growth <br /> had developed large polyps. RAD001 treatment these <br />                                                                                     factor (IGF) using antibody array, revealed significant <br /> Apc&#226;&#338;&#172;716 mice reduced number large-size polyps (&#226;&#172;&#381; 1.5                    difference levels factors polyps between <br /> mm) [supporting information (SI) Fig. S1]. To test                          placebo-treated RAD001-treated Apc&#226;&#338;&#172;716 mice (data not <br /> RAD001-treatment improve mortality Apc&#226;&#338;&#172;716 mouse,                          shown). These results suggest intestinal polyp inhibition <br /> we examined effect long-term treatment Apc&#226;&#338;&#172;716                        RAD001 independent suppression angiogenesis- <br /> mouse RAD001. Although placebo-treated mice                         related factors VEGF Apc&#226;&#338;&#172;716 mice. It reported <br />                                                                                                                                                           MEDICAL SCIENCES <br />  <br />  <br />  <br />  <br /> became moribund 30 weeks age, 50% mice                             rapamycin directly inhibits endothelial cell growth (17, 18). <br /> treated RAD001 10 mg/kg lived &#226;&#172;&#381;1.5 years (Fig. 2F).                         Accordingly, examined p-S6-positive endothelial cells in <br /> These results indicate activation mTORC1 pathway                        adenoma blood vessels double immunostaining p-S6, and <br /> plays important roles polyp formation initiation                     CD31, marker endothelial cells. About 10% angio- <br /> and expansion steps, inhibition mTORC1 path-                        genic vessels adenomas positively stained p-S6 (Fig. <br /> way effective treatment FAP patients.                                 4D). However, endothelial cells normal villi crypts <br />  <br /> Fujishita et al.                                                                                   PNAS &#229;&#8230;&#169; September 9, 2008 &#229;&#8230;&#169; vol. 105 &#229;&#8230;&#169; no. 36 &#229;&#8230;&#169; 13545 <br />  Fig. 2. RAD001 suppresses polyp formation significant effects <span id='am-6' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-7' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-8' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-9' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-10' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-11' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-12' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-13' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-14' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-15' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-16' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-17' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-18' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-19' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-20' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-21' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-22' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-23' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-25' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-26' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-27' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-28' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-29' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-30' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-31' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-32' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-33' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-34' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-35' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-36' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-37' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-38' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-39' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-40' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-41' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-42' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-43' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-44' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-45' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-46' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-47' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-48' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-49' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-50' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-51' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-52' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-53' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-54' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-55' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-56' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-57' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-58' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-59' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-60' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-61' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-62' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-63' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-64' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-65' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-66' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-67' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-69' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-70' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-71' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-72' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-73' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-74' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-75' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-76' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-77' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-78' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-79' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-80' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-81' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-82' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-83' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span>survival</span> Apc&#226;&#338;&#172;716 mouse. (A) Schematic diagram RAD001 treatment schedule. <br /> Mice treated RAD001 day 8 weeks. (B) Number polyps mouse scored (B1), size distribution intestinal polyps (B2), percent <br /> of polyp number size (B3) Apc&#226;&#338;&#172;716 mice treated RAD001. (C) Gross appearance small intestinal polyps. Arrowheads indicate Peyer&#226;&#8364;&#8482;s <br /> patch. Duo, duodenum, Jej: Jejunum; Ile, Ileum. (D) Dissection micrograph small intestine. (E) Cross-section polyp (shown D) cut dotted <br /> line. H&amp;E staining placebo (Upper) RAD001-treated polyps (Lower). (Scale bar: 200 &#226;?&#174;m.) (F) Kaplan&#226;&#8364;&#8220;Meier plot shows survival Apc&#226;&#338;&#172;716 mice treated with <br /> placebo (n &#226;&#171;&#189; 10, black); RAD001, 3 mg/kg (n &#226;&#171;&#189; 9, red); RAD001, 10 mg/kg (n &#226;&#171;&#189; 10, blue). <br />  <br />  <br />  <br /> showed S6 phosphorylation [normal intestine 0% vs. adenoma                        S2B). On hand, AMPK phosphorylation Thr-172 was <br /> 10 &#226;&#171;&#190; 2.8% (Fig. 4D)]. Phosphorylation S6 angiogenic                     elevated 3.3 times polyps, suggesting AMPK pathway <br /> vessels polyps disappeared RAD001 treatment                      suppressed (Fig. S2C). These results indicate mTORC1 <br /> (Fig. 4D). These results suggest RAD001 directly                         pathway activation Apc&#226;&#338;&#172;716 intestinal polyps independent of <br /> inhibit angiogenic vessels suppression mTOR                        Erk AMPK signaling. Nutrients leucine also <br /> pathway reduce blood vessel formation, leading                     activate mTORC1 pathway (21). Starved WT mice showed <br /> regression already-formed polyps.                                          reduction S6 phosphorylation level normal intestinal <br />                                                                                   epithelium compared free-feeding WT mice. In contrast, <br /> The Wnt Signaling Stimulates mTOR Pathway. mTORC1                          starved Apc&#226;&#338;&#172;716 mice did exhibit reduction S6 <br /> stimulated various upstream signals, including emanated                  phosphorylation level polyps compared normal <br /> by growth factors, nutrients, energy, PI3K&#226;&#8364;&#8220;                   tissues, suggesting mTORC1 pathway polyps is <br /> Akt signaling pathway prominent (1). To investigate               independent <span id='am-1' about='Thesaurus:Nutrient' typeof='owl:Thing'>nutrient</span> status (Fig. S2D). These results indicate <br /> mechanism mTOR pathway activation polyps                         mTORC1 constitutively activated polyps Apc&#226;&#338;&#172;716 <br /> Apc&#226;&#338;&#172;716 mice, examined PI3K pathway inhibition                   mice. <br /> would affect mTOR pathway activation status polyps                   To explore activation mechanism mTORC1 path- <br /> treating Apc&#226;&#338;&#172;716 mice wortmannin, potent PI3K inhibitor.                   way, determined mTOR expression levels polyps <br /> Although treatment RAD001 3 days strongly inhibit                  normal intestine Apc&#226;&#338;&#172;716 mice Western blotting and <br /> S6 phosphorylation, wortmannin failed suppress S6 phosphor-                    immunostaining. Expression mTOR protein higher the <br /> ylation Apc&#226;&#338;&#172;716 mouse, dose sufficient inhibit Akt            polyps normal ileum (Fig. 5A). An immunohisto- <br /> phosphorylation (Fig. S2 A). These results indicate pathways                 chemical analysis showed mTOR protein expressed <br /> other PI3K&#226;&#8364;&#8220;Akt pathway activate mTORC1 signaling                     strongly adenoma epithelium proliferative zone <br /> in intestine Apc&#226;&#338;&#172;716 mice. In addition PI3K&#226;&#8364;&#8220;Akt,                crypts Wnt signaling activated (Fig. S3 A&#226;&#8364;&#8220;D). <br /> Raf-Mek1/2-Erk1/2 activation AMP-activated protein kinase                      Increased expression mTOR protein reported for <br /> (AMPK) inhibition activate mTORC1 signaling (19, 20).                     types human tumors, including colon cancer (22, 23), <br /> However, phosphorylation Erk1/2 Thr-202/Tyr-204 re-                     reduced expression mTOR protein impairs mTORC1 <br /> duced 33% polyps compared normal tissue,                    signaling (2). <br /> suggesting Erk pathway activated polyps (Fig.                The intestinal polyps Apc&#226;&#338;&#172;716 mice caused the <br />  <br /> 13546 &#229;&#8230;&#169; www.pnas.org&#229;&#8230;&#190;cgi&#229;&#8230;&#190;doi&#229;&#8230;&#190;10.1073&#229;&#8230;&#190;pnas.0800041105                                                                                              Fujishita et al. <br />  Fig. 3.   RAD001 attenuates adenoma cell growth does induce <br /> apoptosis. (A) Photographs small intestinal adenoma epithelium la- <br /> beled BrdU placebo-treated (Left) RAD001-treated (Right) Apc&#226;&#338;&#172;716 <br /> mouse. (B) BrdU labeling indices small intestinal normal mucosa polyps <br /> in placebo-treated RAD001-treated Apc&#226;&#338;&#172;716 mice. (C) Photographs of <br /> TUNEL assay small intestinal polyps placebo-treated (Left) RAD001- <br />                                                                                   Fig. 4. Treatment RAD001 inhibits angiogenesis polyps Apc&#226;&#338;&#172;716 <br /> treated (Right) Apc&#226;&#338;&#172;716 mouse. (D) Apoptotic indices small intestinal normal <br />                                                                                   mouse. (A) Immunostaining von Willebrand Factor (vWF) luminal side <br /> mucosa polyps placebo- RAD001-treated Apc&#226;&#338;&#172;716 mice. (E) Western <br />                                                                                   small intestinal polyp placebo-treated (Left) RAD001-treated <br /> blot analysis cyclin E cyclin A normal ileum polyps the <br />                                                                                   (Right) Apc&#226;&#338;&#172;716 mouse. (B) Microvessel density (MVD) placebo-treated <br /> Apc&#226;&#338;&#172;716 mouse treated placebo RAD001 (10 mg/kg) 3 days 8 <br />                                                                                   RAD001-treated Apc&#226;&#338;&#172;716 mice. (C) Immunostaining VEGF luminal <br /> weeks. (Scale bars: A C, 50 &#226;?&#174;m.) <br />                                                                                   small intestinal polyp (Right) normal ileum (Left) the <br />                                                                                   placebo-treated (Upper) RAD001-treated (Lower) Apc&#226;&#338;&#172;716 mouse. (D) <br />                                                                                   Immunofluorescence p-S6 (green) CD31 (red) normal crypt villus, <br /> canonical Wnt signaling activation loss heterozy-                  luminal small intestinal polyp Apc&#226;&#338;&#172;716 mouse and <br /> gosity Apc gene (24), leads &#226;?&#164;-catenin stabiliza-                  immunofluorescence luminal small intestinal polyp the <br /> tion. The stabilized &#226;?&#164;-catenin moves nucleus                    Apc&#226;&#338;&#172;716 mouse treated RAD001 1 week (Left Right). Nuclei were <br /> binds TCF/LEF transcription factors increases                      stained DAPI. White arrows indicate double-positive cells. (Scale bars: A <br /> expression Wnt-target genes. To elucidate roles Wnt                 C, 50 &#226;?&#174;m.) (Magnification, D: crypt villus, &#226;&#171;&#187;200; polyps, &#226;&#171;&#187;400.) <br /> signaling activation mTOR signaling regulation, ex- <br /> amined effects &#226;?&#164;-catenin knockdown mTOR pathway <br /> in SW480, colon cancer cell line APC mutations. Trans-                     normal ileum (Fig. S3G). These results indicate Wnt <br /> fection siRNA CTNNB1 gene encoding &#226;?&#164;-catenin                           signaling regulates mTOR expression mRNA levels. To <br /> markedly reduced &#226;?&#164;-catenin protein level SW480 (Fig.                       investigate fluctuation mTOR protein level could <br /> 5B). Consistently, &#226;?&#164;-catenin knockdown suppressed                    affect mTORC1 pathway signaling colon cancer cells, we <br /> TCF-dependent transcription TOPflash reporter gene assays                      constructed mTOR-knockdown SW480 cells using retrovi- <br /> in SW480 (data shown). Notably, Wnt signaling inhibi-                     ral shRNA. Phosphorylation S6 kinase reduced the <br /> tion CTNNB1 knockdown markedly reduced S6 phosphory-                           mTOR knockdown cells compared controls (Fig. <br /> lation Ser-240/244 SW480 cells (Fig. 5B). We examined                  S3H). These results strongly suggest elevated level the <br /> mTOR expression level SW480 cells treated different                   mTOR protein leads activation mTORC1 signaling <br /> siRNAs CTNNB1. Interestingly, mTOR phos-                         intestinal tumors. <br /> phorylation Ser-2448, PI3K-Akt pathway dependent phos- <br /> phorylation site (25), total mTOR level reduced                  Discussion <br /> in CTNNB1 siRNA-transfected SW480 (Fig. 5 C D).                           We shown mTORC1 pathway strongly activated <br /> Reduction total mTOR protein CTNNB1 siRNA                           adenoma epithelium Apc&#226;&#338;&#172;716 mice compared with <br /> also observed colon cancer cell line, DLD-1,                  neighboring normal intestinal mucosa (Fig. 1), that <br />                                                                                                                                                                    MEDICAL SCIENCES <br />  <br />  <br />  <br />  <br /> APC mutated (data shown). These results suggest                   mTORC1 inhibitor RAD001 significantly suppresses polyp for- <br /> Wnt signaling activation increase mTOR expression                         mation mice prolonged survival (Fig. 2). <br /> level itself. We confirmed mTOR mRNA level                              Although APC gene mutations cases of <br /> significantly reduced &#226;&#172;&#8225;60% CTNNB1 siRNA-                                colorectal cancer, CTNNB1 gene mutations, facilitate Wnt <br /> transfected SW480 (Fig. S3 E F). Consistent result,                 signaling &#226;?&#164;-catenin stabilization, reported (26). <br /> expression mTOR mRNA higher polyps                         We confirmed mTORC1 activated intestinal polyps <br />  <br /> Fujishita et al.                                                                                   PNAS &#229;&#8230;&#169; September 9, 2008 &#229;&#8230;&#169; vol. 105 &#229;&#8230;&#169; no. 36 &#229;&#8230;&#169; 13547 <br />                                                                                            (7). So far, however, colon cancer major targets <br />                                                                                           mTORC1 inhibitor trials. mTORC1 inhibitors been <br />                                                                                           shown inhibit proliferation colon cancer cells vitro, <br />                                                                                           effects vary cell lines (33, 34). Our <br />                                                                                           present results demonstrate RAD001 effective <br />                                                                                           spontaneous intestinal tumors mTORC1 signaling <br />                                                                                           activation. In addition, RAD001 treatment dramatically im- <br />                                                                                           proved survival Apc&#226;&#338;&#172;716 mice (Fig. 2F). These results <br />                                                                                           suggest possibility clinical trials using mTORC1 inhibitors <br />                                                                                           early human colon polyps. We noted healthy Apc&#226;&#338;&#172;716 mice <br />                                                                                           treated &#226;&#172;&#381;1 year RAD001 significant number of <br />                                                                                           large polyps malignant progression [diameter &#226;&#172;&#381;2 mm: <br />                                                                                           54 &#226;&#171;&#190; 28, total polyp number: 140 &#226;&#171;&#190; 60 (mean &#226;&#171;&#190; SD (n &#226;&#171;&#189; <br />                                                                                           4) (data shown)]. These results suggest inhibitory <br />                                                                                           effect RAD001 intestinal polyp formation some- <br />                                                                                           attenuated long-term treatment. However, phosphor- <br />                                                                                           ylation S6 eIF4G reduced polyps such <br />                                                                                           Apc&#226;&#338;&#172;716 mice (data shown), indicating inhibitory <br />                                                                                           effect RAD001 mTORC1 pathway itself not <br /> Fig. 5. Wnt signaling positively regulates mTOR protein expression. (A)                   compromised polyps mice. Thus, mecha- <br /> Western blot analysis mTOR, p-S6, S6 normal ileal mucosa (N)            nisms activated polyps make polyps <br /> polyps (P) Apc&#226;&#338;&#172;716 mouse. &#226;?&#164;-Actin shown loading control. (B)               resistant RAD001. Recent reports showed prolonged <br /> Western blot analysis mTOR SW480 cells treated siRNA                   treatment rapamycin altered phosphorylation status of <br /> &#226;?&#164;-catenin. Samples prepared 72 h transfection 40 nM scramble <br />                                                                                           Akt Ser-473 tissues cell lines (35). Consistently, <br /> RNA 40 nM &#226;?&#164;-catenin siRNA (CTNNB1 siRNA-1). &#226;?&#164;-Catenin siRNA dras- <br /> tically inhibit &#226;?&#164;-catenin expression. (C) Two siRNAs &#226;?&#164;-catenin with <br />                                                                                           phosphorylation Akt substrate Foxo1 markedly <br /> different sequences, CTNNB1 siRNA-1 (40 nM) CTNNB1 siRNA-2 (40 nM),                   increased samples long-term-treated Apc&#226;&#338;&#172;716 mice <br /> were used transfection. Samples prepared 72 h transfection. (D)            compared short-term samples (data shown). Be- <br /> Immunofluorescence mTOR (Left) &#226;?&#164;-catenin (Center) SW480 cells                   cause activation Akt pathway involved <span id='am-84' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-85' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-86' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-87' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-88' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-89' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-90' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-91' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-92' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-93' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-94' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-95' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-96' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-97' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-98' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-99' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-100' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-101' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-102' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-103' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-104' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-105' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-106' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-107' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-108' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-109' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-110' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-111' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-112' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-113' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-114' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-115' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-116' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-117' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-118' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-119' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-120' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-121' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-122' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-123' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-124' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-125' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-126' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-127' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-128' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-129' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-130' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-131' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-132' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-133' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-134' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-135' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-136' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-137' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-138' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-139' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-140' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-141' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-142' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-143' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-144' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-145' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-146' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-147' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-148' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-149' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-150' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-151' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-152' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-153' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-154' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-155' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-156' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-157' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-158' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-159' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-160' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-161' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span>cell survival</span>, these <br /> treated 40 nM scramble RNA (Upper) siRNA &#226;?&#164;-catenin (Lower).               results suggest Akt phosphorylation activation induced <br /> (Right) Merged images mTOR (green) &#226;?&#164;-catenin (red). Nuclei                    long-term treatment RAD001 contribute devel- <br /> stained DAPI. (Magnification: &#226;&#171;&#187;400.)                                                   opment large polyps Apc&#226;&#338;&#172;716 mice. Thus more <br />                                                                                           beneficial patients mTORC1 inhibitor combined Akt <br />                                                                                           inhibitors treatment prevention adenomas. <br /> of Ctnb&#226;&#338;&#172;ex3 mice [carrying stabilized &#226;?&#164;-catenin developing                               What activates mTORC1 pathway Apc&#226;&#338;&#172;716 intestinal <br /> intestinal polyps (27)] (data shown). These results suggest                      polyps? We excluded involvement PI3K-Akt, Erk1/2, <br /> activation mTORC1 depends &#226;?&#164;-catenin stabilization,                              AMPK signaling <span id='am-2' about='Thesaurus:Nutrient' typeof='owl:Thing'>nutrient</span> status frequently <br /> rather mutations Apc itself. These results suggest different                    involved mTORC1 activation (Fig. S2 A&#226;&#8364;&#8220;D). Furthermore, <br /> mechanism reported Inoki et al. (28).                                        treatment meloxicam, COX-2 selective inhibitor, did not <br />    We RAD001 affects proliferation                           alter S6 phosphorylation level Apc&#226;&#338;&#172;716 polyps (data not <br /> polyp epithelial cells vivo tumor angiogenesis (Figs. 3                        shown). Recently, Inoki et al. (28) reported inhibition of <br /> 4). Although RAD001 treatment shown reduce level                               GSK3&#226;?&#164; induced Wnt signaling drove mTORC1 signaling <br /> of VEGF melanoma allograft models,&#194;&#167; strong antiangio-                              TSC2 inhibition. Therefore, conceivable that <br /> genic effect RAD001 accompanied down-                                       mTORC1 signaling Apc&#226;&#338;&#172;716 intestinal polyps activated by <br /> regulation VEGF intestinal polyps Apc&#226;&#338;&#172;716 mice (Fig.                         inhibition GSK3&#226;?&#164;. However, kinase activity GSK3&#226;?&#164; <br /> 4C). On hand, mTORC1 inhibitors shown                                 retained polyps normal tissue Apc&#226;&#338;&#172;716 <br /> to inhibit proliferation vascular endothelial cells (29). Ries-                        intestine (data shown). Interestingly, mTOR protein and <br /> terer et al. (17) reported inhibition mTOR rapamycin                           mRNA expression level markedly increased polyps <br /> induced endothelial cell death caspase 3 activation                           compared normal tissue (Fig. 5A Fig. S3G). In <br /> treatment-dependent degradation Akt protein. Some angio-                               addition, siRNA-mediated knockdown &#226;?&#164;-catenin the <br /> genic vessels adenomas showed mTORC1 signal activation                             SW480 colon cancer cell line decreased mTOR mRNA and <br /> (Fig. 4D). These results suggest RAD001 directly targets                             protein levels (Fig. 5 C D Fig. S3 E F) S6 <br /> vascular endothelial cells, results endothelial cell death                       phosphorylation (Fig. 5B). The reduced level mTOR caused <br /> and growth suppression abrogating survival signals                             shRNA suppressed mTORC1 signaling SW480 cells <br /> through Akt, indirectly inhibiting angiogenesis                               (Fig. S3H). To test possibility level mTOR mRNA <br /> through VEGF&#226;&#8364;&#8220;HIF-1&#226;?&#163; pathway (30). COX-2                                      affected proliferation rate, examined the <br /> shown play important roles intestinal polyp expansion                            effect cell-cycle arrest SW480 cells. The level mTOR <br /> Apc&#226;&#338;&#172;716 mice induction tumor angiogenesis associated                           mRNA affected double thymidine block, sug- <br /> with increase level VEGF (11, 31, 32). However,                                 gesting reduced expression mTOR &#226;?&#164;-catenin <br /> preliminary experiments showed COX-2 expression                                  knockdown caused reduced rate proliferation <br /> unaffected RAD001 Apc&#226;&#338;&#172;716 mouse (data shown),                               (data shown). These results suggest regulation the <br /> which consistent data unchanged VEGF                             mTOR level Wnt signaling plays crucial role the <br /> level. Thus, inhibition angiogenesis RAD001 probably                             activation mTORC1. Thus, propose Wnt signaling <br /> independent COX-2 expression polyps.                                          contributes up-regulation mTOR, leading the <br />    Clinical trials using mTORC1 inhibitors caner therapy                          mTORC1 activation (Fig. S4). <br /> underway glioblastoma, lung cancer, renal cell carcinoma                              In conclusion, demonstrated mTORC1 <br />                                                                                           pathway activation plays important roles intestinal polyp <br /> &#194;&#167;O&#226;&#8364;&#8482;Reilly <br />        TM, et al. American Association Cancer Research Meeting, April 16 &#226;&#8364;&#8220;20, 2005,   formation Apc&#226;&#338;&#172;716 mice, RAD001 potently sup- <br /> Anaheim, CA (abstr).                                                                      presses polyp formation significant effects survival. <br />  <br /> 13548 &#229;&#8230;&#169; www.pnas.org&#229;&#8230;&#190;cgi&#229;&#8230;&#190;doi&#229;&#8230;&#190;10.1073&#229;&#8230;&#190;pnas.0800041105                                                                                              Fujishita et al. <br />  These results suggest RAD001 mTORC1 inhib-                                      administrated (five times week) micro emulsion containing 2% (wt/wt) <br /> itors useful agents therapy prevention colon                                 RAD001 diluted distilled deionized water oral gavage. Wortmannin (5 <br />                                                                                                mg/kg day) (Sigma) i.p. administrated 3 consecutive days. <br /> polyps cancers.                                                                               For details polyp scoring, animal survival assay, histological <br />                                                                                                analysis, immunostaining, Western blot analysis, TUNEL analysis, BrdU stain- <br /> Materials Methods                                                                          ing, microvessel density, antibody array, cells culture, transfection RNA <br /> Animals. The construction Apc&#226;&#338;&#172;716 <span id='am-318' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-319' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-320' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-321' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-322' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-323' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-324' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-325' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-326' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-327' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-328' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-329' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-330' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-331' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-332' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-333' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-334' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-335' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-336' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-337' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-338' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-339' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-340' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-341' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-342' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-343' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-344' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-345' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-346' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-347' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-348' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-349' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-350' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-351' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-352' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-353' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-354' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-355' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-356' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-357' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-358' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-359' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-360' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-361' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-362' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-363' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-364' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-365' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-366' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-367' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-368' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-369' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-370' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-371' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-372' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-373' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-374' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-375' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-376' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-377' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-378' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-379' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-380' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-381' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-382' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-383' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-384' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-385' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-386' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-387' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-388' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-389' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-390' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-391' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-392' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-393' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-394' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-395' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span>knockout</span> mice described (24).                    oligonucleotides, retroviral shRNA infection, RT-PCR analysis, quantita- <br /> Male female Apc&#226;&#338;&#172;716 mice aged 6 14 weeks used                            tive RT-PCR analysis SI Text. <br /> treatment group. All animal experiments approved Animal Care <br /> and Use Committee Kyoto University.                                                         ACKNOWLEDGMENTS. We thank Drs. M. Oshima, M. Sonoshita, A. Mat- <br />                                                                                                sunaga scientific discussion Dr. M. Tsujii (Osaka University, Osaka) for <br />                                                                                                SW480 cells. This work supported grants Ministry of <br /> Drug Administration. RAD001 (everolimus) provided Novartis                          Education, Culture, Sports, Science, Technology Japan. T.F. K.A. are <br /> Institutes BioMedical Research. Three 10 mg/kg day RAD001                   Japan Society Promotion Science research fellows. <br />  <br />  <br />  1. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling growth metabolism.          19. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP (2005) Phosphorylation and <br />     Cell 124:471&#226;&#8364;&#8220; 484.                                                                             functional inactivation TSC2 Erk: Implications tuberous sclerosis cancer <br />  2. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation regulation            pathogenesis. Cell 121:179 &#226;&#8364;&#8220;193. <br />     Akt/PKB rictor-mTOR complex. Science 307:1098 &#226;&#8364;&#8220;1101.                             20. Inoki K, Zhu T, Guan K-L (2003) TSC2 mediates cellular energy response control cell <br />  3. Jacinto E, et al. (2004) Mammalian TOR complex 2 controls actin cytoskeleton           growth survival. Cell 115:577&#226;&#8364;&#8220;590. <br />     rapamycin insensitive. Nat Cell Biol 6:1122&#226;&#8364;&#8220;1128.                                       21. Nakajo T, et al. (2005) Glutamine key regulator amino acid-controlled cell <br />  4. Bjornsti M-A, Houghton PJ (2004) The TOR pathway: A target cancer therapy. Nat             growth mTOR signaling pathway rat intestinal epithelial cells. Biochem <br />     Rev Cancer 4:335&#226;&#8364;&#8220;348.                                                                          Biophys Res Comm 326:174 &#226;&#8364;&#8220;180. <br />  5. Majumder PK, et al. (2004) mTOR inhibition reverses Akt-dependent prostate intra- <br />                                                                                                22. Xu G, Zhang W, Bertram P, Zheng XF, McLeod H (2004) Pharmacogenomic profiling of <br />     epithelial neoplasia regulation apoptotic HIF-1-dependent pathways. <br />                                                                                                    PI3K/PTEN-AKT-mTOR pathway common human tumors. Int J Oncol 24:893&#226;&#8364;&#8220;900. <br />     Nat Med 10:594 &#226;&#8364;&#8220; 601. <br />                                                                                                23. Sahin F, et al. (2004) mTOR P70 S6 kinase expression primary liver neoplasms. Clin <br />  6. Podsypanina K, et al. (2001) An inhibitor mTOR reduces neoplasia normalizes <br />                                                                                                    Cancer Res 10:8421&#226;&#8364;&#8220; 8425. <br />     p70/S6 kinase activity Pten&#226;&#171;&#185;/&#226;&#171;&#186; mice. Proc Natl Acad Sci USA 98:10320 &#226;&#8364;&#8220;10325. <br />                                                                                                24. Oshima M, et al. (1995) Loss Apc heterozygosity abnormal tissue building in <br />  7. Easton JB, Houghton PJ (2006) mTOR cancer therapy. Oncogene 25:6436 &#226;&#8364;&#8220; 6446. <br />  8. van Wetering M, et al. (2002) The &#226;?&#164;-catenin/TCF-4 complex imposes crypt pro-              nascent intestinal polyps mice carrying truncated Apc gene. Proc Natl Acad Sci USA <br />     genitor <span id='am-162' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-163' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-164' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-165' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-166' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-167' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-168' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-169' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-170' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-171' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-172' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-173' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-174' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-175' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-176' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-177' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-178' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-179' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-180' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-181' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-182' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-183' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-184' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-185' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-186' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-187' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-188' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-189' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-190' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-191' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-192' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-193' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-194' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-195' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-196' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-197' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-198' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-199' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-200' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-201' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-202' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-203' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-204' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-205' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-206' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-207' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-208' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-209' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-210' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-211' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-212' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-213' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-214' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-215' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-216' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-217' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-218' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-219' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-220' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-221' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-222' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-223' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-224' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-225' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-226' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-227' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-228' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-229' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-230' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-231' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-232' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-233' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-234' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-235' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-236' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-237' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-238' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-239' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span>phenotype</span> colorectal cancer cells. Cell 111:241&#226;&#8364;&#8220;250.                                92:4482&#226;&#8364;&#8220; 4486. <br />  9. Fodde R, Smits R, Clevers H (2001) APC, signal transduction, genetic instability    25. Nave&#194;&#180; BT, Owens DM, Withers DJ, Alessi DR, Shepherd PR (1999) Mammalian target of <br />     colorectal cancer. Nat Rev Cancer 1:55&#226;&#8364;&#8220; 67.                                                    rapamycin direct target protein kinase B: Identification convergence point <br /> 10. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N (2006) mTOR, translation initi-              opposing effects insulin amino acid deficiency protein translation. <br />     ation, cancer. Oncogene 25:6416 &#226;&#8364;&#8220; 6422.                                                    Biochem J 344:427&#226;&#8364;&#8220; 431. <br /> 11. Oshima M, et al. (2001) Chemoprevention intestinal polyposis the. Apc&#226;&#338;&#172;716 mouse      26. Morin PJ, et al. (1997) Activation &#226;?&#164;-catenin-Tcf signal <br /> </body></html>